335 related articles for article (PubMed ID: 9672169)
1. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
[TBL] [Abstract][Full Text] [Related]
2. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
[TBL] [Abstract][Full Text] [Related]
3. Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy.
Bellobuono A; Mondazzi L; Tempini S; Chiodo F; Magliano E; Furione L; Idéo G
J Hepatol; 2000 Sep; 33(3):463-8. PubMed ID: 11020003
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
Di Marco V; Almasio P; Vaccaro A; Ferraro D; Parisi P; Cataldo MG; Di Stefano R; Craxì A
J Hepatol; 2000 Sep; 33(3):456-62. PubMed ID: 11020002
[TBL] [Abstract][Full Text] [Related]
5. Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months?
Bellobuono A; Mondazzi L; Tempini S; Chiodo F; Magliano E; Mondini C; Idéo G
J Hepatol; 1999 Jan; 30(1):8-13. PubMed ID: 9927145
[TBL] [Abstract][Full Text] [Related]
6. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.
Fong TL; Han SH; Tsai NC; Morgan TR; Mizokami M; Qian D; Phan C; Goad K; Redeker AG
J Hepatol; 1998 Mar; 28(3):369-74. PubMed ID: 9551672
[TBL] [Abstract][Full Text] [Related]
7. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C.
Di Marco V; Lo Iacono O; Cammà C; Almasio PL; Vaccaro A; Fuschi P; Giunta M; Fabiano C; Pagliaro L; Craxì A
J Med Virol; 1997 Jan; 51(1):17-24. PubMed ID: 8986944
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.
Farrell G; Cooksley WG; Dudley FJ; Watson K
J Viral Hepat; 1997 Sep; 4(5):317-23. PubMed ID: 9310930
[TBL] [Abstract][Full Text] [Related]
10. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
Engler S; Flechtenmacher C; Wiedemann KH; Gugler R; Stremmel W; Kallinowski B
J Viral Hepat; 2004 Jan; 11(1):60-8. PubMed ID: 14738559
[TBL] [Abstract][Full Text] [Related]
11. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
[TBL] [Abstract][Full Text] [Related]
13. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
14. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
Brouwer JT; Hansen BE; Niesters HG; Schalm SW
J Hepatol; 1999 Feb; 30(2):192-8. PubMed ID: 10068095
[TBL] [Abstract][Full Text] [Related]
15. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.
Lau DT; Kleiner DE; Ghany MG; Park Y; Schmid P; Hoofnagle JH
Hepatology; 1998 Oct; 28(4):1121-7. PubMed ID: 9755252
[TBL] [Abstract][Full Text] [Related]
16. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.
Almasio PL; Di Marco V; Bonura C; Fuschi P; Camma C; Lo Iacono O; Artini M; Natoli C; Di Stefano R; Levrero M; Craxi A
Dig Dis Sci; 1999 May; 44(5):1013-9. PubMed ID: 10235612
[TBL] [Abstract][Full Text] [Related]
17. Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: a multicenter, randomized, controlled study.
Damen M; Weegink CJ; Mauser-Bunschoten EP; Cuypers HT; Hermus MC; Sillekens P; Haan E; van den Berg HM; Bresters D; Lelie PN; Chamuleau RA; Reesink HW
Scand J Gastroenterol; 2001 Jan; 36(1):97-104. PubMed ID: 11218246
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
[TBL] [Abstract][Full Text] [Related]
19. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
[TBL] [Abstract][Full Text] [Related]
20. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial.
Salmerón J; Ruiz-Extremera A; Torres C; Rodríguez-Ramos L; Lavín I; Quintero D; Palacios A
Liver; 1999 Aug; 19(4):275-80. PubMed ID: 10459624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
